Fulgent Therapeutics

Fulgent Pharma is a privately held company dedicated to the development of clinical-stage medications aimed at treating various types of cancer. The company specializes in creating innovative cancer therapeutics, including both enhanced chemotherapy drugs through nanoencapsulation and new drug candidates. Its focus encompasses a wide array of cancers, such as breast, lung, ovarian, colon, and pancreatic cancer, reflecting its commitment to advancing treatment options in oncology.

Inform Diagnostics, Inc. is a healthcare company specializing in anatomic pathology services across various fields, including breast health, dermatology, gastroenterology, hematology, and urology. The company develops a blood-based diagnostics platform aimed at addressing clinical needs in gastrointestinal cancers, focusing on screening, diagnosis, prognosis, and therapeutic guidance. Inform Diagnostics also offers urologic pathology services, including microscopy and immunohistochemistry, and specialized tests such as the EoGenius test for eosinophilic esophagitis and UroVysion, a urine test for bladder cancer detection. Additionally, the company provides general surgery pathology services and consulting related to regulatory compliance for pharmaceutical companies and diagnostic developers. Founded in 1996 and headquartered in Irving, Texas, Inform Diagnostics operates laboratories in Irving, Phoenix, and Boston. The company was previously known as Miraca Life Sciences, changing its name in January 2018, and is a subsidiary of Avista Capital Holdings, L.P.

Spatial Genomics is a leader in spatial analysis, specializing in sequential fluorescence technology that identifies RNA transcripts within individual cells while preserving their spatial context. This innovative approach aids clients in mapping gene expression and contributes to the development of the human cell atlas. By providing tools that facilitate the study of cellular environments, Spatial Genomics aims to establish its technology as a standard research instrument in laboratories globally, thereby enhancing discovery and understanding in the field of genomics.

CSI Laboratories, founded in 1997, specializes in personalized diagnostic testing primarily for the pathology community. Initially established as a flow cytometry laboratory, it has since expanded its services to include cytogenetics and molecular genetics, incorporating fluorescence in-situ hybridization and immunohistochemistry. In 2005, the company broadened its offerings by launching cytogenetics and molecular genetics laboratories and further enhanced its capabilities with an extensive immunohistochemistry laboratory in 2007. CSI Laboratories provides a range of diagnostic services, including next-generation sequencing and consultations for hematopathology and surgical pathology clients. Throughout its operations, the company has maintained a strong commitment to client service and patient care, positioning itself as a vital resource for pathologists and clinicians across the nation.

FF Gene Biotech was founded to bring Fulgent Genetics’ Next Generation Sequencing (NGS) capabilities to the Chinese genetic testing market.

Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. The company’s mission is to simplify cancer screening so lives can be saved by detecting cancer earlier. With Helio’s AI-driven technology, both physicians and their patients gain powerful insights from accurate, accessible, and convenient blood tests. Helio’s development program is focused on liver, colon, breast and lung cancer. Helio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN.